# BATCH2-ACTIVATION-1 — Runtime Activate Cleared Non-Thyroid Batch 2 Subset

**Work ID:** `BATCH2-ACTIVATION-1_runtime_activate_cleared_non_thyroid_subset`  
**Date:** 2026-06-07  
**SOP:** AUTOMATION_BUS_SOP_v1.3.1

---

## Executive verdict

**COMPLETE — Phase 3 runtime activation performed.** Human approval phrase **`APPROVE BATCH2 RUNTIME ACTIVATION`** received and recorded. **6/6** non-thyroid activation candidates runtime-activated via frame index + manifest metadata. **4** thyroid packages remain deferred (TSH-gated). **10** excluded packages untouched. Post-activation architecture gate **PASS**. No medical logic or runtime code changes.

---

## Preflight findings (Phase 1 — prior session)

| # | Check | Result |
|---|-------|--------|
| 1 | Six activation candidate packages found | **Yes** |
| 2 | Four thyroid packages deferred with correct blocker | **Yes** |
| 3 | Ten excluded packages confirmed out of scope | **Yes** |
| 4 | All six candidate packages validate | **6/6 PASS** (pre-activation) |
| 5 | Activation keys unique | **Yes** |
| 6 | No active duplicate activation key | **Yes** |
| 7 | Runtime activation mechanism identified | **Yes** — metadata only |
| 8 | Rollback path defined | **Yes** |
| 9 | No medical logic change required | **Confirmed** |

---

## STOP gate outcome

**Status:** `APPROVED`

**Human approval received:** **Yes**

**Approval phrase:** `APPROVE BATCH2 RUNTIME ACTIVATION`

**Approval recorded at:** `2026-06-07T13:00:00Z` (execution register)

**Activation performed:** **Yes** — Phase 3 on sprint branch continuation

---

## Six runtime-activated packages

| package_id | activation_key | post_activation_state |
|------------|----------------|----------------------|
| pkg_kb47_creatine_kinase_high_exertional_muscle_injury | signal_creatine_kinase_high::inv_creatine_kinase_high_exertional_muscle_injury | runtime_active_canonical |
| pkg_kb47_creatine_kinase_high_persistent_nonexertional_muscle_injury | signal_creatine_kinase_high::inv_creatine_kinase_high_persistent_nonexertional_muscle_injury | runtime_active_canonical |
| pkg_kb47_eosinophil_pct_high_reactive_atopic_eosinophilia | signal_eosinophil_pct_high::inv_eosinophil_pct_high_reactive_atopic_eosinophilia | runtime_active_canonical |
| pkg_kb47_eosinophil_pct_high_secondary_or_systemic_eosinophilia | signal_eosinophil_pct_high::inv_eosinophil_pct_high_secondary_or_systemic_eosinophilia | runtime_active_canonical |
| pkg_kb47_eosinophils_abs_high_reactive_eosinophilic_inflammation | signal_eosinophils_abs_high::inv_eosinophils_abs_high_reactive_eosinophilic_inflammation | runtime_active_canonical |
| pkg_kb47_eosinophils_abs_high_hypereosinophilic_or_secondary_eosinophilia | signal_eosinophils_abs_high::inv_eosinophils_abs_high_hypereosinophilic_or_secondary_eosinophilia | runtime_active_canonical |

---

## Four thyroid runtime-deferred packages

| package_id | deferred_reason | activated |
|------------|-----------------|-----------|
| pkg_kb47_free_t3_high_t3_predominant_thyrotoxicosis | thyroid_activation_requires_tsh_gating | false |
| pkg_kb47_free_t3_low_low_t3_syndrome | thyroid_activation_requires_tsh_ft4_and_illness_medication_context | false |
| pkg_kb47_free_t4_high_thyrotoxicosis_context | thyroid_activation_requires_tsh_gating | false |
| pkg_kb47_free_t4_low_thyroid_hormone_deficiency | thyroid_activation_requires_tsh_gating | false |

---

## Ten excluded packages

All androgen (8) + eGFR (2) — **confirmed untouched**.

---

## Runtime authority files changed

| File | Change |
|------|--------|
| `knowledge_bus/governance/medical_frame_identity_index_v1.yaml` | 6 frames → `runtime_active_canonical` / `active` / `accepted_with_rationale` |
| 6 × `package_manifest.yaml` | Added `governance_runtime_activation_*` metadata |
| `knowledge_bus/governance/batch2_runtime_activation_execution_register_v1.yaml` | Approval + activation recorded |

**No changes to:** signal_library.yaml, research_brief.yaml, promoted_signal_intelligence.yaml, thresholds, activation_key, signal_id, clinical wording, frontend, evaluators, loaders, SSOT.

---

## Rollback path

Revert for the six activated packages only:

1. `medical_frame_identity_index_v1.yaml` — set `promotion_state: compiled_not_promoted`, `runtime_authority_status: inactive`, restore prior `clinical_adjudication_status`
2. Remove `governance_runtime_activation_*` fields from the six package manifests
3. Update execution register to record rollback

Thyroid, androgen, and eGFR packages remain untouched by rollback.

---

## Post-activation validation output

See gate run output captured at commit time. Expected:

```text
architecture_validation_gate: PASS
validation_status: PASS (frame index)
6/6 validate_knowledge_package.py: PASS
```

---

## Carry-forward updates

| ID | Action |
|----|--------|
| CF-BATCH2-012 | **Resolved** — 6/6 non-thyroid packages runtime-activated |
| CF-BATCH2-013 | **Open** — TSH-gated thyroid activation logic still required |
| CF-BATCH2-007 | Remains Open |
| CF-BATCH2-010 | Remains Open |
| CF-CONTEXT-MOD-3 | Remains Open |

---

## Final Batch 2 activation status

| Subset | Status |
|--------|--------|
| Governance promotion (10) | **Complete** |
| Runtime activation (6 candidates) | **Complete** |
| Thyroid (4) | **Deferred pending TSH-gated activation logic** |
| Androgen + eGFR (10) | **Excluded** |

---

## Confirmations

- No runtime/frontend/evaluator **code** changes
- No medical logic changes
- No excluded package file changes
- No thyroid package activation
